1. Advances in autoantibody testing
2. Ankylosing spondylitis
3. Antiphospholipid syndrome
4. Artificial intelligence and autoimmune rheumatological diseases
5. Autoimmunity to the autonomic nervous system
6. Autoinflammatory diseases
7. Biological drugs
8. Biomarkers in autoimmune rheumatological conditions
9. CAR-T cells and autoimmune rheumatological diseases
10. Checkpoint inhibitors induced autoimmunity
11. Circulating extracellular vesicles
12. Comorbidity in rheumatic and autoimmune diseases
13. COVID and autoimmunity
14. Environment, epigenetic and genetic
15. Etiology, genetics and mechanisms in rheumatic and autoimmune diseases
16. Fibromyalgia, chronic pain and pain relief
17. Gout
18. Idiopathic inflammatory myopathies
19. IgG4 related diseases
20. IL17, TH17 and cytokines in autoimmunity
21. Immunometabolism and autoimmunity
22. Infection and autoimmunity
23. Innate and adaptive autoimmunity
24. Interstitial lung diseases
25. IVIG and natural autoantibodies
26. Microbiome, probiotic and nutritional factors in autoimmune and rheumatological diseases
27. Miscellaneous
28. Novel aspects of therapies – biosimilars
29. Novel therapeutic targets in rheumatological and autoimmune diseases
30. Omics and multi-omics in autoimmune and rheumatological diseases
31. Organ involvement in autoimmune rheumatic diseases
32. Pathogenetic and protective autoantibodies
33. Patient reported outcomes in autoimmune and rheumatological diseases
34. Pediatric rheumatology
35. Pregnancy and autoimmunity
36. Psoriatic arthritis
37. Pulmonary arterial hypertension & systemic sclerosis
38. Refractory autoimmune diseases
39. Registries and cohorts
40. Rheumatoid arthritis
41. Sjögren’s disease
42. Small molecules and inhibitors
43. Spondyloarthritis
44. Spondyloarthropathies​
45. Systemic lupus erythematosus – clinical aspects
46. Systemic lupus erythematosus – pathogenesis
47. Systemic lupus erythematosus – therapies
48. Systemic sclerosis – clinical aspects and treatment
49. Systemic sclerosis – pathogenesis
50. Thyroid autoimmunity
51. Vasculitides

*The CORA 2025 abstract submission guidelines and key dates will be published shortly.